MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Total Liabilities 2011-2026 | NDRA
Annual Total Liabilities ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.89 M | 1.1 M | 2.07 M | 2.09 M | 1.6 M | 2.42 M | 975 K | 848 K | 1.38 M | 236 K | 97.6 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.42 M | 97.6 K | 1.34 M |
Quarterly Total Liabilities ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.79 M | 1.33 M | 1.42 M | 1.89 M | - | 1.45 M | 1.36 M | 1.1 M | 2.41 M | 2.31 M | 2.16 M | 2.07 M | 2.14 M | 1.98 M | 1.87 M | 2.09 M | 2.16 M | 2.25 M | 1.05 M | 1.6 M | 2.03 M | 1.6 M | 1.6 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 975 K | 975 K | 975 K | 975 K | 848 K | 848 K | 848 K | 848 K | 1.38 M | 1.38 M | 1.38 M | 1.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.42 M | 848 K | 1.63 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
5.32 B | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | USA |
 |
Celcuity
CELC
|
130 M | $ 107.62 | -0.63 % | $ 4.25 B | USA |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 13.82 | -2.68 % | $ 418 M | USA |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
75.4 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 175.77 | -1.61 % | $ 8.71 B | USA |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.75 B | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K |  Israel |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 315.61 | -0.56 % | $ 27.1 B |  Schweiz |
|
Biodesix
BDSX
|
76.4 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
523 M | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
73.5 M | $ 13.37 | -3.47 % | $ 328 M | USA |
 |
Natera
NTRA
|
689 M | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
41.3 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
31.8 B | $ 204.04 | -0.9 % | $ 145 B | USA |
 |
Organovo Holdings
ONVO
|
4.16 M | - | -2.3 % | $ 19.4 M | USA |
 |
OPKO Health
OPK
|
835 M | $ 1.22 | -2.02 % | $ 847 M | USA |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
590 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
7.26 M | $ 10.3 | -4.19 % | $ 292 M | Israel |
 |
DexCom
DXCM
|
3.59 B | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
4.92 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
5.65 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
3.67 M | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
255 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Burning Rock Biotech Limited
BNR
|
433 M | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
2.7 B | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
Renalytix AI plc
RNLX
|
15.8 M | - | 5.66 % | $ 22.7 M | Britain |
 |
VolitionRx Limited
VNRX
|
35.5 M | $ 0.2 | -0.74 % | $ 19.2 M |  Singapore |